Orphan Medical Stockholders Approve Acquisition by Jazz Pharmaceuticals, Inc.
22 Junho 2005 - 1:26PM
Business Wire
Orphan Medical, Inc. (NASDAQ:ORPH) announced that its stockholders,
voting at a special meeting held this morning, have approved the
proposed acquisition of the Company by Jazz Pharmaceuticals, Inc.
An affirmative vote by Orphan Medical's common and senior preferred
stockholders, voting together as a single class owning 7,716,833
shares of common stock on an as-converted basis, which represents
61.4 percent of the outstanding shares of common and senior
preferred stock entitled to vote, and 94.2 percent of the shares
voted, approved the transaction. The proposed combination was
announced on April 19, 2005, and is expected to close on June 24,
2005, subject to satisfaction of customary closing conditions.
Under the terms of the merger agreement, Orphan Medical's
stockholders will receive $10.75 in cash for each share of Orphan
Medical common stock that they own. About Orphan Medical Orphan
Medical acquires, develops, and markets pharmaceuticals of high
medical value for inadequately treated and uncommon central nervous
system diseases treated by specialist physicians. The Company's
lead product is Xyrem, which is the first and only approved
treatment for cataplexy associated with narcolepsy. Xyrem is being
assessed as a treatment for the full range of narcolepsy symptoms
including excessive daytime sleepiness. The Company is also
conducting a trial to evaluate Xyrem as a treatment for symptoms of
fibromyalgia syndrome. Orphan Medical's Internet Web site address
is www.orphan.com.
Orphazyme AS (NASDAQ:ORPH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Orphazyme AS (NASDAQ:ORPH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Orphazyme AS da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Orphan Medical, Inc.